Back to top
more

ABM Industries (ABM)

(Delayed Data from NYSE)

$47.74 USD

47.74
336,260

+0.51 (1.08%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $48.00 +0.26 (0.54%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (97 out of 244)

Industry: Business - Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's What Key Metrics Tell Us About ABM Industries (ABM) Q3 Earnings

by Zacks Equity Research

While the top- and bottom-line numbers for ABM Industries (ABM) give a sense of how the business performed in the quarter ended July 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

ABM Industries (ABM) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

ABM Industries (ABM) delivered earnings and revenue surprises of 10.59% and 2.75%, respectively, for the quarter ended July 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

HealthEquity Stock May Gain From Its Latest Partnership With Paytient

by Zacks Equity Research

HQY collaborates with Paytient to enhance employees' access to healthcare through Health Payment Accounts.

Zacks Equity Research

Intuitive Surgical Gains 40.5% Year to Date: What's Driving the Stock?

by Zacks Equity Research

ISRG's shares gain on the back of strength in da Vinci surgical system.

Zacks Equity Research

HealthEquity Stock Rises on Q2 Earnings and Revenue Beat

by Zacks Equity Research

HQY surpasses second-quarter expectations on robust HSA growth and improved margins. It also raises FY25 guidance.

Zacks Equity Research

AngioDynamics Stock Falls Despite CE Mark for Auryon System

by Zacks Equity Research

ANGO's Auryon Atherectomy System earns CE Mark, which expands its European market reach and enhances PAD treatment with advanced laser technology.

Zacks Equity Research

Greenville Center to Boost CAH Stock's at-Home Solution Business

by Zacks Equity Research

Cardinal Health announces the opening of its new distribution center in Greenville to support its at-Home Solutions business.

Zacks Equity Research

Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI

by Zacks Equity Research

FEMY's eco-friendly FemVue MINI receives CE Mark and Health Canada approval, advancing sustainable fallopian tube assessment technology in Europe and Canada.

Zacks Equity Research

Delcath Systems Stock Gains on Positive CHEMOSAT Melanoma Data

by Zacks Equity Research

DCTH's study of the CHEMOSAT Hepatic Delivery System shows that the device significantly boosts survival rates in uveal melanoma patients with liver metastases, outperforming systemic therapies.

Zacks Equity Research

DaVita Rallies 44% Year to Date: What's Driving the Stock?

by Zacks Equity Research

DVA's shares gain on the back of strong fundamentals. However, dependence on commercial payers can be a cause of concern.

Zacks Equity Research

Seeking Clues to ABM Industries (ABM) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for ABM Industries (ABM), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended July 2024.

Zacks Equity Research

QuidelOrtho Expands in Infectious Disease Testing With New FDA Nod

by Zacks Equity Research

QDEL announces the FDA's clearance for its VITROS syphilis assay, which boosts the company's infectious disease testing portfolio.

Zacks Equity Research

iRhythm Technologies Launches Zio Monitoring Across Europe

by Zacks Equity Research

IRTC launches Zio monitor in Austria, Netherlands, Spain and Switzerland, which offers 14-day continuous ECG monitoring, enhancing arrhythmia diagnosis and patient care.

Zacks Equity Research

Are Investors Undervaluing ABM Industries (ABM) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Veeva Systems Q2 Earnings & Revenues Beat, Operating Margin Up Y/Y

by Zacks Equity Research

VEEV's fiscal second-quarter results reflect impressive performance by the Subscription services segment, along with the expansion of gross and operating margins.

Zacks Equity Research

Maravai LifeSciences' Cygnus & TriLink Unveil AccuRes DNA Kits

by Zacks Equity Research

MRVI's Cygnus and TriLink introduce AccuRes kits, setting a new standard in host cell DNA quantification with unmatched sensitivity and specificity.

Zacks Equity Research

Accuray Stock Rises After Helix System Wins CE Mark for Cancer Care

by Zacks Equity Research

ARAY's Helix system, now CE Mark approved, aims to close global cancer care gaps with cost-effective, high-throughput radiotherapy for underserved regions.

Zacks Equity Research

Stryker Rallies 19.8% Year to Date: What's Driving the Stock?

by Zacks Equity Research

SYK's flagship Mako Total Knee Platform, its strategic acquisitions and a diversified product portfolio raise optimism about the stock.

Zacks Equity Research

AtriCure's Shares Likely to Benefit From New AtriClip Device Sales

by Zacks Equity Research

ATRC announces the treatment of the first patient using the AtriClip FLEX-Mini device.

Zacks Equity Research

DexCom Stock May Gain on Expanded Reach After Stelo's US Launch

by Zacks Equity Research

DXCM announces that its OTC CGM, Stelo, is now available for purchase in the United States without a prescription.

Zacks Equity Research

Is HealthEquity Stock a Hold Now Amid Strong Top-Line Growth?

by Zacks Equity Research

HQY's sustained strength in HSAs raises optimism about the stock.

Zacks Equity Research

GE Healthcare to Unveil AI-Driven Cardiac Diagnostics at ESC 2024

by Zacks Equity Research

GEHC launches AI-enhanced ultrasound and ECG-less Cardiac CT technologies, offering rapid, accurate cardiac diagnostics at the point of care.

Zacks Equity Research

Teleflex's (TFX) Titan SGS Stapler Showcases Positive Outcomes

by Zacks Equity Research

Teleflex (TFX) publishes an analysis of clinical data showcasing the Titan SGS Stapler's enhanced clinical outcomes and significant efficiency benefits.

Zacks Equity Research

Inari Medical (NARI) Issues Notice Post ClotTriever XL Recall

by Zacks Equity Research

Inari Medical (NARI) issues urgent updates to ClotTriever XL Catheter instructions following the FDA's recall after reports of serious injuries and deaths.

Zacks Equity Research

AtriCure's (ATRC) AtriClip Receives Expanded CE-Mark Indication

by Zacks Equity Research

AtriCure (ATRC) announces the receipt of an expanded CE-Mark indication for its AtriClip devices for reducing strokes in patients with Afib.